Literature DB >> 6727550

Prolidase and prolidase deficiency.

I Myara, C Charpentier, A Lemonnier.   

Abstract

Prolidase deficiency seems to be a rather rare metabolic disorder. However, many new cases can be detected because screening is easy to perform and enzymatic confirmation allows the differentiation from other iminodipeptidurias . Clinical symptoms are briefly reviewed, while biological considerations and prolidase properties are exhaustively described. Methods for investigating urinary iminodipeptides are given with results. Moreover, several collagen modifications observed in this disorder led us to formulate a hypothesis for their mechanism. Genetic considerations and treatment attempts are discussed.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6727550     DOI： 10.1016/0024-3205(84)90363-1

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  37 in total

1.  Enhanced prolidase activity and decreased collagen content in breast cancer tissue.

Authors:  Marzanna Cechowska-Pasko; Jerzy Pałka; Marek Z Wojtukiewicz
Journal:  Int J Exp Pathol       Date:  2006-08       Impact factor: 1.925

2.  Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium.

Authors:  Ina Hubatsch; Lucia Lazorova; Anders Vahlne; Per Artursson
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Collagen metabolism disturbances are accompanied by an increase in prolidase activity in lung carcinoma planoepitheliale.

Authors:  E Karna; A Surazynski; J Palka
Journal:  Int J Exp Pathol       Date:  2000-10       Impact factor: 1.925

4.  Presence in human cells and tissues of two prolidases and their alteration in prolidase deficiency.

Authors:  J Butterworth; D A Priestman
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

5.  Prolidase deficiency breaks tolerance to lupus-associated antigens.

Authors:  Biji T Kurien; Anil D'Sousa; Benjamin F Bruner; Timothy Gross; Judith A James; Ira N Targoff; Jacen S Maier-Moore; Isaac T W Harley; Heng Wang; R Hal Scofield
Journal:  Int J Rheum Dis       Date:  2013-12-14       Impact factor: 2.454

6.  Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer.

Authors:  Ewa Karna; Arkadiusz Surazynski; Kazimierz Orłowski; Joanna Łaszkiewicz; Zbigniew Puchalski; Piotr Nawrat; Jerzy Pałka
Journal:  Int J Exp Pathol       Date:  2002-10       Impact factor: 1.925

7.  Prolidase activity and oxidative status in patients with thalassemia major.

Authors:  Alpay Cakmak; Murat Soker; Ahmet Koc; Nurten Aksoy
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

8.  Prolidase deficiency: it looks like systemic lupus erythematosus but it is not.

Authors:  Aharon Klar; Paulina Navon-Elkan; Alan Rubinow; David Branski; Haggit Hurvitz; Ernst Christensen; Morad Khayat; Tzipora C Falik-Zaccai
Journal:  Eur J Pediatr       Date:  2009-11-24       Impact factor: 3.183

Review 9.  Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery.

Authors:  J P Bai; G L Amidon
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

10.  Insulin-like growth factor I-dependent regulation of prolidase activity in cultured human skin fibroblasts.

Authors:  W Miltyk; E Karna; S Wołczyński; J Pałka
Journal:  Mol Cell Biochem       Date:  1998-12       Impact factor: 3.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.